PEPG
PepGen Inc (PEPG)
Healthcare • NASDAQ • $2.57-1.15%
- Symbol
- PEPG
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.57
- Daily Change
- -1.15%
- Market Cap
- $179.84M
- Trailing P/E
- N/A
- Forward P/E
- -2.45
- 52W High
- $7.80
- 52W Low
- $1.31
- Analyst Target
- $10.19
- Dividend Yield
- 0.00%
- Beta
- 2.01
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Company websiteResearch PEPG on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.